GVA Asset Management Discloses 5.50% Holding in Reyon Pharmaceutical After Convertible Bond Price Adjustment

• GVA Asset Management disclosed a 5.5% holding in Reyon Pharmaceutical, representing 1,081,612 potential shares through convertible bonds, as of October 19, 2026.
• An October 16 conversion-price reduction to 10,170 won increased potential shares by 153,969, triggering the initial 5% disclosure.
• The holding is for passive investment purposes.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Reyon Pharmaceutical Co. Ltd. published the original content used to generate this news brief via DART, the regulatory disclosure system operated by the South Korea Financial Supervisory Service (FSS) (Ref. ID: 20261020000373), on October 20, 2026, and is solely responsible for the information contained therein.